AstraZeneca Reports the Data from PURSUIT P-IIb Study Evaluating AZD0780
Shots:
- AstraZeneca presented data at the ACC'25 and simultaneously published data in JACC from the PURSUIT P-IIb study (n=480) evaluating the efficacy, safety, and tolerability of AZD0780 (1mg, 3mg, 10mg & 30mg QD) added to SoC statin therapy vs PBO in dyslipidemic patients with LDL-C levels ≥70 and <190 mg/dL on moderate or high intensity statins, with or without ezetimibe
- In the study, n=426 started treatment, QD AZD0780 30mg with SoC reduced LDL-C by 50.7% at 12 weeks, regardless of baseline statin intensity. Furthermore, AZD0780 achieved LDL-C target (<70 mg/dL) in 84% of participants, vs 13% on statin therapy alone, based on AHA/ACC guidelines
- AZD0780 was well tolerated, and data from PURSUIT are consistent with P-I findings presented at the EAS’24
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Calquence (Acalabrutinib) Plus Chemoimmunotherapy Receives the CHMP’s Positive Opinion for 1L Mantle Cell Lymphoma (MCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
